

## Biophytis Appoints Pierre J. Dilda as Director of Research

**Paris (France) & Cambridge (Mass), 1 December 2015 – Biophytis (Alternext Paris : ALBPS), a geriatric medicine company advancing clinical stage drug-candidates to treat sarcopenic obesity and age related macular degeneration (AMD), today announced that it appoints Pierre J. Dilda, PhD, Director of Research.**

French-Australian, Dr Dilda has more than 20 years of experience in pharmaceutical research, in both academic and industrial settings. Since 2002, he was Senior Research Fellow at the Lowy Cancer Research Center at the University of New South Wales (UNSW) in Sydney, Australia, where he was responsible for advancing several cancer therapeutics into advanced clinical development. Previously, he held several positions of responsibility for research and development at Mayoly Spindler Laboratories, a French pharmaceutical company. He received his PhD in Pharmacology from University Paris V and is an author on more than 50 peer reviewed publications.

At Biophytis Dr Dilda will be in charge of preclinical development for drug candidates emanating from the company's discovery platform, including the lead drug-candidates targeting sarcopenic obesity (*i.e.* Sarcob: BIO101 and BIO103) and dry age related macular degeneration (AMD) (*i.e.* Maculia: BIO201 and BIO203). In addition, Dr. Dilda will oversee the continued utilization of the discovery platform as well as collaborations with academic and, potentially, future industrial partners. In addition, Dr Dilda will take responsibility for the companies growing intellectual property portfolio, which protects Sarcob, Macula, future molecules and related technologies.

"I am thrilled to welcome Pierre to our team," said Stanislas Veillet, PhD, CEO of Biophytis. "His contributions will be essential for the continued application and future development of our platform for discovery of first-in-class therapeutics targeting diseases of aging. In this newly created position, Pierre will bring his international industrial experience and support our Chief Scientific Officer and co-founder, Professor René Lafont, PhD, in advancing development of our therapeutic-candidates, enlarging our platform's capacity and establishing our world-leading research."

**Biophytis SA ([www.biophytis.com](http://www.biophytis.com)),** founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has discovered and begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing next year: Sarcob (BIO101) to treat sarcopenic obesity and Maculia (BIO201) to treat dry age-related macular degeneration (AMD).

The company was founded in partnership with researchers at the UPMC (Pierre et Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute.

BIOPHYTIS is eligible for the French PEA-PME regime.

**Biophytis**  
**Stanislas Veillet**  
CEO  
contact@biophytis.com  
Tel : +33 1 41 83 66 00

**Milestones**  
**Bruno Arabian**  
barabian@milestones.fr  
Tel : +33 1 83 62 34 84  
Mob : +33 6 87 88 47 26

**LifeSci Advisors**  
**Chris Maggos**  
Managing Director, Europe  
chris@lifesciadvisors.com  
Tel : +41 79 367 6254